Japan is legendary for its focus—many would say obsession—on producing high-quality products. When it comes to sourcing active pharmaceutical ingredients (APIs), Japanese generic drug firms are ...
Japan’s pharmaceutical industry is undergoing a period of transformation, and the contract development and manufacturing organization (CDMO) of large molecule active pharmaceutical ingredients (APIs) ...
Japan's government is looking to procure more generic drugs to help relieve its healthcare budget, and Eisai intends to cash in on that shift by offering its own India-made APIs to competitors. It is ...
Japan has a large, well-developed pharmaceutical market and offers universal health coverage to its citizens. The country has one of the most advanced research and development facilities across the ...
Daiichi Sankyo will close an active pharmaceutical ingredients (API) plant in Hiratsuka, Japan, by September 2017. Opened in 1962, the facility employs 150 people and is one of Daiichi Sankyo’s four ...
The FDA slapped Japanese API maker Yuki Gosei Kogyo with a warning letter, citing the Tokyo-based company for failing to report lab testing data on released lots. The warning letter was in response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results